Publication: Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.
Loading...
Identifiers
Date
2022-09-28
Authors
Raj, Kavita
Eikema, Dirk-Jan
Sheth, Vipul
Koster, Linda
de Wreede, Liesbeth C
Blaise, Didier
Di Grazia, Carmela
Koc, Yener
Potter, Victoria
Chevallier, Patrice
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p
Description
MeSH Terms
Adult
Cyclophosphamide
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Middle Aged
Myelodysplastic Syndromes
Neoplasms
Recurrence
Retrospective Studies
Siblings
Transplantation Conditioning
Unrelated Donors
Cyclophosphamide
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Middle Aged
Myelodysplastic Syndromes
Neoplasms
Recurrence
Retrospective Studies
Siblings
Transplantation Conditioning
Unrelated Donors